Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paris Chloé, Curmin Raphaëlle, Gouillon Laurie, Giboin Caroline, De Rycke Yann, Bachelez Hervé, Beneton Nathalie, Beylot-Barry Marie, Dupuy Alain, Joly Pascal, Mahé Emmanuel, Paul Carle, Richard Marie-Aleth, Sbidian Émilie, Viguier Manuelle, Chosidow Olivier, Tubach Florence, Jullien Denis, PSOBIOTEQ study group
Аннотация
BACKGROUND: There are limited data on the impact of the route of administration of methotrexate (MTX) on drug survival in psoriasis.
OBJECTIVE: To evaluate the impact of the initial route of administration of MTX (monotherapy) on drug survival in patients with moderate to severe skin psoriasis.
MATERIALS AND METHODS: A prospective cohort study based on the Psobioteq registry, included from July 2012 to January 2023, patients with plaque, erythrodermic or guttate psoriasis, naive to MTX, biologics and apremilast, who initiated MTX monotherapy. Factors associated with drug survival were identified using Kaplan-Meier curves and Cox regression analyses.
RESULTS: In total, 406 patients were included, 58.1% received MTX per os (MTX-PO) and 41.9% subcutaneously (MTX-SC). At MTX initiation, the median PASI score was 11, and 67.3% had DLQI ≥6. Adjusted drug survival did not statistically differ according to the route of administration (p = 0.15).
LIMITATIONS: Limited number of patients leading to a potential lack of power. Residual confounding cannot be waived due to the observational nature of the data.
CONCLUSIONS: Overall MTX survival did not significantly differ according to the route of administration. However, with MTX-SC, the hazard of discontinuation for ineffectiveness was lower and of discontinuation for intolerance was higher than with MTX-PO.
OBJECTIVE: To evaluate the impact of the initial route of administration of MTX (monotherapy) on drug survival in patients with moderate to severe skin psoriasis.
MATERIALS AND METHODS: A prospective cohort study based on the Psobioteq registry, included from July 2012 to January 2023, patients with plaque, erythrodermic or guttate psoriasis, naive to MTX, biologics and apremilast, who initiated MTX monotherapy. Factors associated with drug survival were identified using Kaplan-Meier curves and Cox regression analyses.
RESULTS: In total, 406 patients were included, 58.1% received MTX per os (MTX-PO) and 41.9% subcutaneously (MTX-SC). At MTX initiation, the median PASI score was 11, and 67.3% had DLQI ≥6. Adjusted drug survival did not statistically differ according to the route of administration (p = 0.15).
LIMITATIONS: Limited number of patients leading to a potential lack of power. Residual confounding cannot be waived due to the observational nature of the data.
CONCLUSIONS: Overall MTX survival did not significantly differ according to the route of administration. However, with MTX-SC, the hazard of discontinuation for ineffectiveness was lower and of discontinuation for intolerance was higher than with MTX-PO.